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Introduction for Annual Report 1990
The “winds of change” blow across
medicine as a whole effecting patients
and their families, their physicians, and
the institutions within which they
receive medical care. More information
about a medical problem and potential
alternative treatments is often re
quested by the patient and given by
their physicians. Participatory decision
making is encouraged. Regrettably,
insurance companies and governmen
Marcia J. S. Richards, M.D.
tal programs at times seem to weave a
web of detours and delays in personal
medical journeys. And the final chal
lenge for all of us together is to evaluate the cost and
effectiveness of medical procedures, and if need be to
make individual and societal choices.
This environment of medical care in transition presents
special problems for the patient and their family confronted with cancer. Recognizing the need and desire for
more information to be made available to concerned
individuals in this increasingly complex and humanly
often intimidating health care system, the Cancer Committee at St. Luke’s Medical Center is trying an experiment
with this year’s Annual Report yes, a clincal trial of sorts.
We want this year not just to inform the physicians who
care for cancer patients on the activities of the Cancer
Program at St. Luke’s Medical Center, but to create a
unique institutionally personal resource for patients and
their families focusing on the most common cancer in men
prostate cancer.
-

-

Please participate with us; let us know if we are pursuing a
useful course with this change from the past by responding
on the enclosed evaluation.
Marcia J. S. Richards, M.D.
Chair/Cancer Committee
St. Luke’s Medical Center
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Care and Treatment of Prostate Cancer
Introduction

The era of the 90’s has ushered in new
awareness of men’s health problems.
Just as the 80’s centered on women’s
health concerns, especially breast
cancer early in the decade and ovarian
cancer in the latter part, the 90’s has
centered on the concern of the male
population and the second leading
cause of cancer deaths prostate
cancer.
-

Barry H. Usow, M.D.

Each year 106,000 cases occur with a
death toll of 30,000 men. Vast research
has been going on in the epidemiology
as well as the early detection of this disease. It has been
stated in the urologic literature for years that if a man lives
long enough, he will develop prostate cancer. But who is
most at risk? What diagnostic tools are available for early
detection? When found, which cancer will go on to
impair a man’s life and which will never cause him a
problem? These are some of the questions still needing
answers.
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Early detection is the key to effective treatment and
survival.

Preventing prostate cancer is not possible but the key to
treatment and survival is early detection. The standard
rectal examination is still important but along with this a
new blood test, prostatic specific antigen, has been devel
oped as a marker to follow progression of disease and
possibly detect early cancers before one can feel it.
Transrectal ultrasound helps us look at the prostate and
provides easier biopsy techniques. Other x-ray and diag
nostic tools are also being utilized to evaluate the extent of
disease. The surgical treatment of localized disease has
changed drastically with the thorough understanding of
the nerve and vascular supply to the male genital region
and prostate. Not only can men maintain continence and
potency but their quality of life is much improved.
Radiation therapy for localized disease has changed with
the ability to pinpoint treatment to maximize beam penetration where it is most needed with less tissue damage.
Larger glands, which used to be thought too large for
cure, can be treated with newer modalities irridium
implants, hormonal manipulation and chemotherapy.
-

Barry H. Usow, M.D.
Urology
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Incidence
Cancer of the prostate has become the
z:.
number one cancer in American men,
and the second leading cause of cancer
f
deaths It is estimated that in 1990 there
Y
)
will be 106,000 newly diagnosed cases
j ‘ri
and 30,000 cancer deaths Approxi
mately 1 man in 12 will develop prostate
cancer during his lifetime, and in AfroAmerican males this incidence is 1 in 10
Less than one percent of prostate cancer
Elliott Silbar, MD.
cases are detected before age 50, but it
becomes increasingly common with
each decade of life. Over 80 percent of
all cases are diagnosed in men over 65, with a median age
of 72 years at diagnosis.
.
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The incidence of prostate cancer has increased 47% from
1973 to 1987. This increased incidence of prostate cancer is
thought secondary to several factors: better methods of
detection, including prostate specific antigen levels, and
transrectal ultrasound; increased efforts at early diagnosis;
and the aging of the population, with more people at risk.
Cumulative data from several autopsy series have demonstrated that the pathologic prevalence of prostate cancer is
greater than the clinical prevalence. The frequency of
prostate cancer in the fifth, sixth, seventh, and eighth
decades of life were 8%, 22%, 37°A, and 53%. Several
factors explain this high incidence of prostate cancer
found at autopsy. Because prostate cancer cells are felt to
have an extremely long doubling time of about 6 months,
it has a long natural history from inception to death of
about 20-30 years.
Most prostate cancer remains clinically undetectable at the
time of death (death occurring from other causes). Tu
mors which have undergone more divisions, thus reaching larger volumes are more likely to be clinically detected
and result in disease progression.
Epidemiology
Solid evidence for a particular etiology of prostate cancer is
not available, but many factors are felt to play a role.
Hormonal effects
Changes in the sex hormone milieu occur with advancing
age and thus have been implicated in the etiology of
prostate cancer. Other factors suggesting a hormonal
influence include: the presence of steroid hormone recep
tors in the prostate, the androgen dependence for normal
prostatic growth, the failure of prostate cancer to develop
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Care and Treatment ofProstate Cancer

in men castrated before puberty, the favorable clinical
response to androgen ablation in men with advanced
prostate cancer, and the ability to induce prostate cancer in
laboratory rats by administering exogenous testosterone
and estrogen.
Genetic influences
Some studies suggest a genetic predisposition to prostate
cancer and an increased risk for blood relatives of men
with the disease.
Race
Afro-American men have the highest reported incidence of
prostate cancer worldwide; Oriental men have the lowest.
The observation that immigrants from low-risk countries,
such as those coming from Japan to the U.S., have mcidence figures between those of the country of origin and
the U.S. implies that in addition to race, environmental
factors may play an important role.
Environmental factors
An increased risk of prostate cancer has been documented
in men living in industrialized countries, and in men
residing in urban areas compared against those residing in
rural areas.
Diet
The association between diet and prostate cancer remains
controversial. Some studies suggest a diet rich in fat
increases the risk of the disease.
Occupational exposure
Occupational exposure to carcinogens, especially cadmium
which is used in welding, electroplating, and in alkaline
batteries may increase the risk of prostate cancer.
Infectious agents
The possible role of sexually transmitted viral diseases in
the development of prostate cancer is still being explored.
Benign prostatic hypertrophy (BPH)
The incidence of both prostate cancer and BPH increases
with age and are often found simultaneously. However,
the relationship between prostatic carcinoma and
hyperplasia remains controversial and undefined.
Clinical presentation
It must be emphasized that in the early stages of prostate
cancer, there may be no symptoms. At the time of presen
tation 56.8% of patients have localized disease, 19.5%
regional involvement, and 23.7% have distant metastases.
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The majority of patients have either an asymptomatic
prostatic nodule discovered on digital rectal examination
or bladder outlet obstructive symptoms. The symptoms
of obstructive uropathy due to carcinoma are identical to
those from BPH, and may include diminution in the force
and caliber of the urinary stream, hesitancy in initiating
voiding, terminal dribbling, sensation of incomplete
emptying, urinary frequency, nocturia, and retention.
Patients may also have moderate irritative bladder symp
toms in the absence of infection, but isolated hematuria or
hematospermia is unusual.
Patients with metastatic prostate cancer most often com
plain of bone pain. Lower extremity edema, renal failure,
visceral metastases, anemia, or cachexia may also be the
presenting symptom.
Conclusions
The incidence of prostate cancer can be expected to only
increase. Although often considered an indolent neo
plasm, only 71% of patients with prostate cancer will have
10 year survival comparable to that of the general popula
tion. Patients dying of prostate cancer will lose approxi
mately 9 years of life. The best way to decrease the impact
of prostate cancer is to work toward early detection of the
disease and to further the research of epidemiology so
those at risk can be identified.
Elliott Silbar, M.D.
Urology
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Care and Treatment ofProstate Cancer

Prostate Screening

Because of the major impact prostate
cancer has on the male population in
the United States, early detection has
become a pressing issue. With early
diagnosis and effective local control,
the course of the disease can be altered
and the mortality reduced.
Routine rectal examination has been
the most effective method available for
screening. The American Cancer
KerryA. Twite,
Society
recommends that all men over
R.N., M.S.N., O.C.N.
the age of 40 have a digital rectal
examination as part of a yearly physical examination.
‘

-

_i

In September 1990, as part of the second annual public
education effort of the Prostate Cancer Education Council,
St. Luke’s Medical center offered free prostate screenings.
The goal of the Prostate Awareness Week was to focus
public attention on prostate cancer and to urge men over
the age of 40 to get a digital rectal examination that could
detect the disease at a curable stage. More than 150,000
men were screened nationwide.
St. Luke’s screened 234 men during the week long screenings. Fifty two individuals were found to have an abnor
mal digital rectal exam (22%).
A questionnaire which identified risk factors, lifestyle
habits, past medical history, family history, and significant
signs and symptoms, was completed by all participants
prior to the digital rectal exam (DRE). Men screened were
given educational materials on prostate cancer and prostate health and a sheet indicating the results of their DRE.
Any individual with abnormal findings was counseled to
follow-up with a physician, and a letter indicating the
results of the exam was sent to his personal physician.
All but one of the men screened at St. Luke’s were over the
age of 40. The largest number of men screened were
between the ages of 61 and 70 years old. An abnormal
DRE was found in individuals ranging from 36 years old to
greater than 80 years old. The highest frequency occurred
in the 65-69 year old group.
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In looking at health care practices, 36% of the participants
had a complete physical exam within the past year, but
only 26% indicated that they had had a DRE within the
last year. Among those who had an abnormal DRE, 38%
had a physical within the past year, and 33% had a DRE
performed within the past year. Twenty seven percent of
those who had a digital rectal exam within the past year
had it performed by an urologist.
It is significant to note that 15 of the 52 individuals with an
abnormal DRE indicated they had an enlarged prostate in
the medical history.
Participants were asked to identify urinary and associated
symptoms within the past 6 months. Sixty-nine of the
men screened indicated they experienced no symptoms.
Eleven individuals with an abnormal DRE were
asymptomatic. Among those with an abnormal DRE, the
most frequent symptoms reported were: need to go to the
bathroom frequently at night, weak urine stream, a strong
need to urinate but little urine comes out, and pain or
burning on urination.
Follow-up contacts with those individuals with abnormal
DRE revealed that 42 individuals had been seen by a
physician. Of these, 24 indicated they had been to see an
urologist. Three individuals were diagnosed with poorly
differentiated adenocarcinoma of the prostate as a result of
the prostate screenings. One patient was diagnosed in late
October after an incisional biopsy and has since completed
radiation therapy. The second individual underwent a
TURP and bilateral orchiectomy for prostate cancer staged
as T2N1M1 The third patient was diagnosed in Novem
ber 1990 and underwent a radical prostatectomy with
bilateral lymph node dissection.
.

The response of the Milwaukee community to the prostate
screenings was overwhelming. Prostate screening can be
a valuable tool in the prevention and early detection of
prostate cancer.
Kerry A. Twite, RN., M.S.N., O.C.N.
Clinical Nurse Specialist, Oncology
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A prostate screening prograni, started 2 years ago at
St. Lit/a’ ‘s Medical Center, has increased public
awareness, earh diagnosis and treatine;zt of this
disease.
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Prostatic Specific Antigen
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Jeffrey A. Derus, M.D.

The traditional method of detecting
prostate cancer is the digital rectal ex
amination which is the most cost-effec
tive method to screen large populations
of men. However, there are several
limitations to this examination. Not all
cancers occur in an area accessible to the
examiner’s finger. Not all tumors are
large enough to palpate. In the screened
population the cancer detection rate
with rectal examination is only 1.3 to
l.7%.

For years investigators have searched for
the ideal tumor marker. The ideal marker would be prostate cancer specific, indicative of the tumor’s grade, stage
and volume, reflective of prognosis and inexpensive. Recently, a prostatic enzyme has been identified, characterized
and found to be produced exclusively by prostatic tissue.
This enzyme is called “prostatic specific antigen,” which
was first isolated by Dr. Wang and associates in 1979. Prostatic specific antigen is produced by prostatic epithelial cells,
not stromal cells, and is responsible for liquification of
seminal coagulant. PSA is present in normal, hyperplastic
(BPH), and neoplastic prostate tissue within the gland as
well as metastatic sites. PSA is prostate specific but not
prostate cancer specific.
There are several commercially available assays to measure
serum prostatic specific antigen. The Tandem-R assay
(Hybritech) is a monoclonal antibody immunoradiometric
assay with a stated upper normal limit of 4.0 ng/ml.
Proscheck (Yang) is a polyclonal radioimmunoassay with an
upper normal limit of 2.5 ng/ml. Factors that may elevate
serum prostatic specific antigen include digital rectal exami
nations (O-l.9x), cystoscopy (4x), prostatic needle biopsy
(57x), TURP (53x), prostatitis, urinary retention and possible
prostatic infarction. The PSA rises with age, but there is no
diurnal or circadian variation. The half life of PSA is 2.2-3.2
days. One should wait 2-3 weeks before attempting to
measure a reliable serum level after prostatic manipulation.
PSA AND BPH
PSA is organ specific and, as a result, it is produced by
normal hyperplastic and cancerous prostatic tissue. Ap
proximately 2$% of all men with benign prostatic hyper
plasia have an elevated PSA level of greater than 4.0 ng/ml
(Hybritech). It has been determined that serum PSA is
elevated by 0.3 ng/ml (Hybritech) per gram of benign
prostatic tissue. However, this is not a consistent relationship.
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PSA and prostatic carcinoma
Prostatic carcinoma elevates the serum PSA lO-12x as much
as a similar volume of benign prostatic hyperplasia.
Serum PSA increases with histologic grade and rises
progressively as tumor stage increases. However, these
are not linear relationships and there is considerable
overlap between levels of PSA and various cancer stages.
Serum PSA is the most effective study available today for
monitoring patients known to have prostatic carcinoma.
Its serial use serves as an indicator of disease status
following any type of treatment (surgery, radiation and/
or hormonal therapy). And, it is an indicator of disease
progression in those patients who are being managed
expectantly.
PSA as an immunohistochemical marker
Since PSA is organ specific it has been used extensively as
an immunohistochemical marker for prostate cancer.
Numerous studies have shown PSA to be highly specific
and sensitive for all types of prostate tissue. The greatest
role of PSA as an immunohistochemical marker has been
to establish definitively whether a metastatic
adenocarcinoma is of prostatic origin.
PSA in early detection and screening of prostate cancer
The ideal serum tumor marker is one that is expressed
only by cancer cells and can be detected with reliability at
the time the tumor is biologically active. A good screening tool must be safe and inexpensive. The disease being
sought should be common to the population and effective
treatment should be available at a low stage of disease.
The test must be capable of identifying patients with
curable disease from men with benign conditions of the
prostate (benign prostatic hyperplasia). Studies have
shown that 43%) of patients with organ confined prostate
cancer have a PSA value within the normal range and 25%
of patients with benign prostatic hyperplasia have a PSA
value above the normal reference range (4.0 ng/ml). Due
to the tremendous overlap in PSA values between these 2
groups and irrespective of the cut off chosen, the usefulness of PSA alone as an early detector or screening tool for
curable prostate cancer on an individual basis is not
apparent. However, if combined with the digital rectal
examination and/or transrectal ultrasound, prostatic
specific antigen may lead to the detection of more early,
curable prostate cancers.
Jeffrey A. Derus, M.D., Urology
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Prostatic Ultrasonography
an d B iopsy
•

Early detection of prostatic cancer is essential to curing the
disease. At the present time, if the tumor has spread
beyond the confines of the capsule into distant lymph
glands and blood vessels, treatment is palliative rather
than curative. A screening method for early detection that
is more specific and sensitive than the digital rectal exam
is needed. At the present time, a screening tool with l00%
efficacy does not exist. However, transrectal
ultrasonography (TRUS) with or without biopsy is an
exciting and encouraging development.
Over the past few years, ultrasonography has developed
into one of the most commonly used methods of safe
diagnosis. It poses little danger of biological effect to the
patient. In the past, it was not possible to get the ultrasound transducer close enough to the prostate. That has
recently changed, with the development of a hand-held
rectal probe. The transducer is mounted in a thin probe,
and inserted into the rectum, allowing better visualization
of prostate. Two scanning planes are used for proper
orientation: a transaxial plane which is perpendicular to
the rectal anus and a sagital plane which is oriented paral
lel to the rectum. The difference in the echogenicity is the
key to interpretation. Tissues are analyzed as isoechoic,
hyperechoic, and hypoechoic. It is generally felt that most
tumors of the prostate are hypoechoic, although any
pattern can be seen with the diagnosis. There are excep
tions to this rule, e.g. diffuse, non-nodular carcinoma,
which will appear as isoechoic. Once the entire prostate is
visualized in both scanning planes plus the bladder,
seminal vesicles, and even the rectal wall, it is relatively
easy to biopsy any lesion under ultrasound visualization.
Through the same instrument, a biopsy is performed
without the need for anesthesia using a device called a
“biopsy gun.” The spring-loaded needle (size 22) with a
trigger mechanism is able to obtain a core biopsy in a brief
moment. This method is more accurate and less painful
than other biopsy methods. Bleeding and infection are
possible but rare complications.
The indications for TRUS with or without biopsy are:
1) a patient with a prostatic nodule, with or without an
elevated prostatic specific antigen (PSA)
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2) any patient with an elevated PSA, even though the
rectal exam feels normal
3) those with known prostatic carcinoma
4) men needing evaluation of inflammatory prostatic
disease
5) occasionally in individuals with fertility problems to
evaluate the seminal vesicles
The diagnosis and staging of prostate cancer has markedly
improved through the use of transrectal prostatic
ultrasonography (TRUS) with or without core biopsy.
John D. Silbar, M.D.
Urology

Au ttltrasoztiid ijitage of stage B adciiocarcinoiiia of the
prostate. The area oftitiiior iiivolveiiieiit is otttliiied by
airows.
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Diagnostic Imaging of
Prostate Cancer

Several diagnostic imaging modalities
are currently available to assist in the
diagnosis and staging of prostate
cancer.
Transrectal ultrasonography (TRUS) of
the prostate has a number of applica
tions. TRUS may be used to evaluate
patients who have an abnormal
screening digital rectal examination
prostate-specific anti$en level.
and/or
Peter A Coole M D
Jf a suspicious area is identified by
TRUS, ultrasound-guided needle
biopsy may be utilized to confirm the
diagnosis. TRUS and biopsy may also be useful when
prostate cancer is incidentally discovered after
transurethral resection of the prostate performed for
benign prostatic hyperplasia. TRUS may assist in the local
staging of confirmed prostate cancer. Accurate staging is
important in the selection of the appropriate mode of
therapy. Patients with disease confined to the prostate
(stages A and B) and possibly minimally invasive stage C
disease are generally treated surgically by radical
prostatectomy. More advanced localized spread and
distant metastases (stage D) are generally treated with
radiation, hormones and/or chemotherapy. Since TRUS
may detect extracapsular extension of tumor, it is useful in
differentiating stage B from stage C disease. Limitations
of TRUS for staging include its low sensitivity for detecting seminal vesicle invasion and inability to detect more
distant metastases.
.

yl

.
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Computed Tomography scanning has been used for staging purposes. However, CT is limited by its inability to
define the internal architecture of the prostate and has a
relatively low sensitivity in differentiating stage B from
early stage C disease. CT is useful for detecting locally
advanced disease and lymph node metastases and for
radiation treatment planning.
Magnetic resonance imaging (MRI) is a relatively recent
modality in prostate imaging, used primarily for staging
purposes. MRI can display the internal architecture of the

12
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prostate. In addition, extracapsular extension of the
cancer, seminal vesicle involvement, bladder invasion, and
lymph node metastases may all be detected by MRI.
Image quality, and consequently the accuracy of staging
by MRI, have been considerably enhanced by the recent
development of endorectal surface coils. MRI has been
shown in a number of studies to be the most accurate of
the various imaging modalities in the staging of prostate
cancer.
Radionuclide bone scanning remains the procedure of
choice in demonstrating skeletal metastases from prostate
cancer. CT and MR scanning may incidentally demonstrate regional bony metastases but are not useful for
screening purposes.
With expected improvements in technology in the future,
it is hoped that these imaging procedures will be even
more useful in the management of the patient with prostate cancer.
Peter A. Cooley, M.D.
Radiology

A inagiictic resonance image ofstagc’ B
aJ;deJzocarcillt)Illa of the prostate. The areti
i1lvol—oe11l(’ll t iS oittliiicd by arrows.
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Surgical Cure of Prostate
Cancer

Recttirn
.

Bladder

Prostate
Urethra

Penis

A drawing of the male anatomy, showing the
prostate ‘s location.

The decade of the 1980s brought to men
with cancer of the prostate an excellent
chance for cure of their disease. A new
surgical procedure, minimizing risks
to the patient, has revolutionized the
care of men with cancer of the prostate.
After the diagnosis of cancer of the
prostate has been determined through
hssue analysis, men undergo staging
tests to determine if there is evidence of
cancer outside the prostate. If these
Samuel I. Otto, M.D.
staging tests show the tumor is confined to the prostate, and there are no
other significant contraindications, this
man is a good candidate for potentially
curative prostatic surgery.
The surgical procedure, radical retropubic prostat
,
is done in two stages under the same anesthesia. ectomy
The
first
stage involves the removal of lymph node tissue to help
determine the need for additional or alternative cancer
care. If these lymph nodes are free of tumor, the
ist
proceeds to the second stage of the procedure; theurolog
remov
al
of the prostate and seminafvesicles (structures
are
not essential for healthy, normal lives), severingwhich
ure
thra and bladder neck in the process. The urethrathe
is then
reconnected to the bladder neck. A urinary cathete
r is left
in the bladder for approximately three weeks.
patient
remains in the hospital for about one week and The
then
is
sent home.
When the catheter is removed, there is frequently some
transient urinary leakage which resolves spontaneously
in
the vast majority of men. The convalescence is six
weeks
during which walking and mild exercise are benefit
to
the recovery of the patient. After this period,amen
may
return to their normal activities.
Men with cancer of the prostate are concerned about
ability to maintain a normal sexual life following thistheir
kind
of surgery. Often their function is preserved, but it must
be remembered that the primary objective of the
ist
is to cure the patient, and it becomes necessary, aturolog
times, to
remove nerves (which control potency) involved by
tissue. There are options for restoring potency after tumor
the
recovery period.
Many men are cured of this insidious disease each
year
through radical retropubic prostatectomy. This
is docu
mented through careful follow-up with their urolog
ist.
Today urologists can offer a potentially curative,
low risk
procedure to their patients that has revolu
d care for,
and give hope to men afflicted with cancertionize
of the prostate.
Samuel J. Otto, M.D.
Urology
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lhIormonJ Treaiment for
Prostaite Caer

Hormonal therapy for prostate cancer
is reserved for those patients with
spread of the tumor beyond the confines of the prostate gland There is no
w
significant chance for curing the tumor
in these people Hormonal treatment is
aimed at removing or markedly decreasing the male hormone testosterone, which is a potent stimulus for
y
prostate cancer By removing this
/
pain . and fatigue. which is
stimulus, the
.
William Annesley M.D.
often associated with metastatic prostate cancer is thereby relieved. This
form of therapy may not increase
survival, but it can significantly improve quality of life.
There are currently three established forms of hormonal
treatment. These include monthly injections of a substance
(Zoladex or Lupron) which indirectly inhibit formation of
testosterone. Another form is a tablet (Eulexin) which is
taken three times per day and prevents testosterone from
binding to the tissues where it normally has its affect. The
third way of lowering testosterone is by surgically remov
ing the testicles from the scrotum, since these produce the
majority of testosterone in the body. A fourth modality is
also taken as a tablet (Diethylstilbestrol), but is now
infrequently used due mainly to aggravation of heart
problems. All three therapies, whether used alone or in
combination, are about equally effective and there are
advantages/ disadvantages to each. Prostate cancer is
best treated when it is confined to the prostate gland itself.
However, if the tumor has spread and is causing signifi
cant symptoms, then hormonal therapy can be extremely
effective in improving the quality of life in the affected
individual.
.
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General Stage At Diagnosis For Prostate Cancer

William Annesley, M.D.
Urology

1985 vs 1990
1990

1985

According to Cancer Facts &
Figures 1990, 60% ofall Prostate
Cancers are dIscovered while still
localized. This trend has been
notedfor 1985 as well and 1990
Prostate Cancer cases at St. Luke’s
Medical Center.

LOCAL

_\

-

LOCAL 634%
DSANI 100%

7
E_i”RLCONAL 138%
UNKNOWN 13%

(87 Patients)
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Radiation Treatment for
Prostate Cancer

When a prostate cancer is found,
radiation therapy can play a vital role
in the treatment of this disease. Modem radiation techniques have been
available for the treatment of prostate
cancer for longer than 30 years. During
this time period, irradiation estab
lished an outstanding record of safety
and effectiveness in the treatment of
prostate malignancy.
James H. Taylor, MD.

The majority of prostate cancers are
localized at the time of diagnosis. For
early stage prostate carcinoma, radia
tion therapy rivals radical surgery in its ability to control
the tumor and prolong survival. Radiation therapy can be
especially valuable for elderly patients and those patients
with medical problems which would make surgical
resection too risky. External beam irradiation is given on
an outpatient basis to safely treat men who could not
tolerate curative surgery. In selected patients with limited
stage prostate cancer a radiation implant may be recom
mended in addition to external beam irradiation. The
implant requires the insertion of radiation containing
catheters into the prostate gland, under anesthesia. This
approach allows high dose irradiation to the cancer with
relative sparing of adjacent normal tissues.
If, at the time of diagnosis, a prostate cancer is found to
extend beyond the prostate gland involving adjacent
tissues, surgery usually cannot be performed for cure.
Fortunately curative doses of radiation can still be given.
Similar to localized prostate cancer, there is a choice
between external beam radiation alone or external treatments combined with a radioactive implant.
Even in patients whose prostate cancer has spread to the
bones or other organs, radiation therapy can prove invalu
able in maintaining an optimal quality of life. A brief
course of treatment to the painful area often provides
gratifying relief of discomfort with minimal side effects.
While irradiation for prostate cancer has an established
record of safety and effectiveness, ongoing developments
continue to improve tumor control while decreasing the
risks of complications. The use of high energy radiation
allows the dose of radiation to be better localized. Here at
St. Luke’s Medical Center two high energy linear accelera
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tors assure that every patient has access to state of the art
treatment equipment. Recent clinical studies have better
defined the appropriate treatment volumes and doses for
patients with various stages of prostate cancer. Irradiation
treatments are customized for each patient accounting for
individual differences in cancer, size, location, and normal
anatomy. The x-ray beam is shaped to avoid normal
tissues (bowel and bladder) which are not involved with
cancer. Continuing developments are improving the
effectiveness of radiation therapy. Radiation therapy is a
vital component in the overall treatment of patients with
prostate cancer.
James H. Taylor, M.D.
Radiation Oncology

I
I

An implant delivers a high dose ofradiatio;i, contained
catheters, to the prostate cancer.
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Chemotherapy Treatment For
Prostate Cancer

FIRST COURSE OF TREATMENT
ALL STAGES
TREATMENT
SURGERY ONLY

42

RADIATION ONLY

j

HORMONES ONLY

10.7

SURGERY & RADIATION

B4

SURGERY & HORMONES
OTHER
NONE

13.7
J38
61
0

10
20
30
40
PERCENTAGE OF PATIENTS TREATED

1990 Total number of patients

50

131

According to a professional educational publication

from the American Cancer Society, it is not yet

possible to choose the optimal treatmentfor the varying
stages ofprostate cancer. There has been an increased
Iocus on indicators such as tumor grade and stage in
order to assist in choosing a possible mode of therapy.

The treatment of prostate cancer has
improved survival. Prolonged life is
related to whether this disease is
localized within the prostate, is regionally localized within the limiting
capsule of the prostate or has spread
beyond the prostate gland into pelvic
nodes or the lungs, bones or liver.
Treatment options are influenced by
the extent of disease, concurrent medi
John P. Hanson, Jr., M.D. cal problems, and age. Treatments
employing radiation or surgery for
both local and regional disease may be
appropriate. A surgical exploration of the nodes around
the prostate to define if the disease involves nodes beyond
the prostate is accepted as a valuable tool in obtaining
information for the best management. Complications
from surgery have been reduced as the surgical execution
has become more precise and is able to spare nerves
responsible for potency. Improvement in radiation treatment planning has reduced the bladder and bowel
irritation. Treatment for more advanced and wide-spread
cancers is based on the principles of blocking androgens
which act as a growth factor. Bilateral removal of the
testes has equally good results as using medication such as
Lupron. Surgery, radiation and hormonal therapy have
improved survival in these patients. Chemotherapy will
begin to play a more accepted role in the management of
these patients in light of the new FDA guidelines to
measure benefit from drug therapy. The goal of clear
palliation without a concurrent demonstration of survival
is clearly an acceptable goal for chemotherapy.
Adriamycin, 5-FU and Cisplatin have been shown to cause
responses. Studies are underway to find the role of immu
notherapy in prostate cancer. At present, there is no clear
evidence of improvement of survival or consistent
palliation.
Johr P. Hanson, Jr., M.D.
Medical Oncology
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Impotence may result from radical

.

radicalcystectomyfrombladdercancer
and iadical surgery for cancer of the
rectum These surgical procedures
often sacrifice the nerves and blood
supply necessary for potency
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Fortunately, there are several veiy
effective treatments for impotence
The most successful surgery to produce
StUal’t W fine, MD.
an erection is a penile implant, surgically placed in the corporeal bodies (the
blood filling spaces of the penis).
These devices were developed in the early 1960’s and have
proved effective for over one million men. There are
several types of implants but the inflatable penile prosthe
sis produces the most natural and esthetically functional
erection.
Another excellent treatment is the use of vasoactive drugs.
These drugs, when injected into the blood filling spaces of
the penis increase blood flow resulting in an erection.
Patients are taught self-injection and generally are very
pleased with this result.
Another treatment option is the use of suction or vacuum
devices. These devices use a cylinder which is placed over
the penis. When a vacuum is created blood flow may
increase, and a band or ring is slipped over the base of the
penis to trap the blood. These devices are effective in some
cases, but are cumbersome to use and are esthetically
deficient.

5 YEAR SURVIVAL
BY GENERAL SUMMARY STAGE
PERCENTAGE OF CASES

.

Impotence resulting from radical cancer surgery of the
pelvis can be successfully treated in the majority of men.
Stuart W. Fine, M.D.
Urology

80

Percent of Patients Surviving by Stage

Yearl
Year 2
Year3
Year 4
Year 5

LOCAL

REGIONAL

95%
86%
80%
70%
68%

92%
75%
56%
33%
33%

%\

°

%

%

%

DISTANT ALL STAGES
89%
67%
22%
11%
fl%

94%
83%
71%
59%
57%

20
ALL CASES
_

LOCAL

- -

REGIONAL

-

DISTANT
—

UNKNOWN

Our patient with an unknown/undetermined stage graphed above has a 5 year survival
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Pain Control of Prostate
Cancer

Michael A. Farina, RPh

:

Prostate cancer is now the most com
mon non-skin cancer affecting men.
The treatment of prostate cancer
depends on the stage of the disease,
physical status and age of the patient.
The pain associated with prostate
cancer can usually be controlled and
successfully managed by a variety of
treatment modalities. The clinical
pharmacist can make a difference in
these pain modalities. Pharmacists
collaborate with the Cancer Pain
Management Team to contribute to the
patient’s care by educating staff,
maintaining current reference materi
als and by acting as a drug information
resource identifying potential drug
with drug interactions when multiple
therapies are prescribed.

Ii

The use of oral analgesic agents is the
mainstay of treatment for cancer pain.
Adequate analgesia can be achieved in
the large majority of patients if sound
harmacolo ical rinci les are emJona an ay,
ployed. Use of agents appropriate for
the nature and severity of the patient’s
pain is essential in controlling both the
pain and anxiety created by these disease states. Pain
control is made easier for patients by the availability of
newer drug delivery systems such as controlled release
morphine tablets or transdermal (through the skin)
fentanyl patches which improve pain relief and facilitate
patient compliance. Other drugs such as nonsteroidal
anti-inflammatory drugs, tricyclic antidepressants,
anticonvulsants, corticosteroids and others may be added
to narcotic analgesics to maximize pain control. Most
cancer patients have a long-term venous access device.
When oral therapy is not possible, this parenteral route
allows for continuous analgesic therapy. Portable ambula
tory infusion pumps make home infusion of these drugs
possible and pain therapy more convenient for the patient.
.

/

.

An anesthesiologist may be consulted at times to prescribe
epidural pain control which delivers medications 50-100
times stronger than morphine or with advanced disease to
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provide pain relief with a variety of neurodestructive
nerve blocks. The local recurrence or bony metastasis
common to prostate cancer may require radiation therapy
or orthopedic intervention (for pariologic femur fracture).
Epidural techniques may permit the temporary control of
pain to facilitate manipulating the patient for radiation
therapy to proceed. Epidural narcotics are frequently
combined with dilute local anesthetics which can be
carefully titrated using pumps for both outpatient and
inpatient management. These methods may restore
patients to virtually normal activities of daily living.
Once the proper medication is selected and the dosing
interval prescribed, the pharmacist provides expertise to
assure that serum and tissue levels are maintained. A
change from the oral route to an alternative route, often
requires an equivalency calculation which the pharmacist
can provide. Daily monitoring of therapy enables the
health team members to anticipate and promptly treat any
side effects of these drugs. Overall, pharmacy participa
tion with the members of the multidisciplinary team at
St. Luke’s Medical Center assures patients full access to all of
the resources available to successfully manage their cancer
pain.
Michael A. Farina, RPh
Clinical Oncology Pharmacist
Jonathan Kay, M.D.
Anesthesiology

Pain associated with prostate cancer can usually be successfully
managed by a variety oftreatrnent modalities.
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Support Groups for Adults
Experiencing Cancer

“Coming to a support group made
me realize I was not the only one with
this disease. It helps me to talk to
someone who has the same thing you
do,” remarked Nelson Brockway, a
patient with prostate cancer.
St. Luke’s Medical Center offers two
.1’
support groups for adults experiencing
cancer Your Caring Connection is a
:
support group for people whose lives
have been touched by cancer and
Ginny Bourne,
Make Today Coimt, is a support group
RN., M.S.N., C.N.S.
for persons affected with a life-threatening disease. More and more people
are joining support groups which offer
hope, encouragement and the opportu
nity to share concerns in a safe, caring
environment. It has long been thought
that support groups can improve one’s
mental attitude and sense of wellbeing. It was recently reported that
support groups boost survival rates.
David Spiegel, M.D., Associate
Terry Ann Tingwald,
Professor of Psychiatry and Behavioral
R.N., B.S.N., NC.
Science at Stanford University School
of Medicine, believes support group
therapy has been shown to be beneficial for metastatic
breast cancer patients and should become an integral part
of oncology treatment. In his ten year study of women
with metastatic breast cancer, those who participated in a
weekly support group survived almost twice as long as the
control group. Both groups received the same aggressive
treatment, however, those in the control group received no
psychosocial intervention. Support groups offer a forum
to share experiences and feelings, obtain information
about cancer and its treatment, receive emotional support
for those recently diagnosed with cancer, those
undergoing treatment, or those who have completed their
treatment. There is an opportunity for open discussions
about coping, adjusting and problem solving. As
Brockway stated, “coming to support groups makes people
realize they are not alone.” Support groups encourage
new approaches to life, relationships and treatment in this
time of physical and emotional upheaval.
1

.

%

Ginny Bourne, R.N., M.S.N., Clinical Nurse Specialist
Thanatology/Oncology
Terry Ann Tingwald, R.N., B.S.N., Nurse Clinician
Thanatology/Oncology
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Social Work and Prostate
Cancer

About 106,000 men are diagnosed with
prostate cancer in the U.S. every year.
Many of these men are elderly. If
retired, the older man may face less
radical social and financial changes
than does the younger man who
additionally may face physical limita
tions that directly affect employment
or sexuality.
However, upon diagnosis both groups
Grace lessen McCutcheon,
enter the new territory called “cancer
M.S.S.W.,
A.C.S.W.
survivorship,” with its own popula
tion, biology, language, and psychol
ogy. In the last few years better
methods to manage pain and the side effects of treatment
have been developed, and public awareness of prostate
cancer and early detection methods has increased, but the
fundamental personal issues awakened by the diagnosis
remain to affect not only the patient but his family and
support system.
Much of the treatment of prostate cancer will be delivered
in the outpatient setting so the patients’ families and
personal support people are actively involved in the
process. Social work services are available to both inpa
tients and outpatients to arrange for:
1)
2)
3)
4)

community or home health assistance
counseling about long-range financial and insurance planning
eligibility for governmental disability or retirement benefits
coping with the lifestyle changes and emotional challenges
engendered by the disease process

We assist the patient and his/her support system to become mobilized on their own behalf, so that they can
retain as much control of their lives as possible, and that
their decisions can be congruent with their own expecta
tions, beliefs, and goals.
Grace Jessen McCutcheon, M.S.S.W., A.C.S.W
Oncology Social Worker
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Cancer support groups and social services are available
at St. Lithe’s Medical Center to help patients with
personal issues.

New Developments
Apheresis Center of
St. Luke’s Medical Center

August 1991 marked the opening of the
new Apheresis Center, which is an
enhancement of the services provided
through the Cancer Program at St.
Luke’s Medical Center. Apheresis is a
term derived from the Greek word
“aphairesis” meaning “taking away.”
The term pheresis is commonly applied
to a number of technical procedures in
a component of the patient’s
which
I Y ;
collected and processed. A
is
blood
Marija Barthel, R.N.,B.S. V.
prefix is added to the term “pheresis”
to indicate exactly what is being
removed (e.g. plasmapheresis is the
removal of plasma, leukapheresis is the removal of the
white blood cells).
The plasmapheresis procedure has been shown to be
beneficial in the treatment of a variety of diseases that
require removal of specific plasma factors from the blood.
The staff of the Medical-Respiratory Intensive Care Unit
currently perform this procedure. The procedure is used
to treat diseases such as myasthenia gravis, Guillian Barre,
and multiple myeloma.
Pheresis also plays a part in the exciting research being
conducted through the Immunotherapy Program for
patients with metastatic kidney cancer, melanoma and
other advanced cancers. In this case, the procedure is
called leukapheresis. Patients receive a drug called
Interleukin 2 (IL-2) over a period of several days. This
drug enhances the cancer fighting ability of a particular
group of white blood cells called lymphocytes. The
lymphocytes are then removed from the blood using the
pheresis procedure.
This is done daily for four days. The staff of the Vince
Lombardi Cancer Clinic have been specially trained to
perform the leukapheresis procedure. The cells removed
are immersed in a solution of IL-2, where they start to
multiply and are transformed into Lymphokine Activated
Killer (LAK) cells. These LAK cells are then reinfused into
the patient and target the cancer cells.
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The apheresis procedure also plays a role in autologous
bone marrow transplantation. In this case, the apheresis
procedure is again called leukapheresis. Stem cells are
collected during the apheresis procedure. These immature
cells have the ability to grow and multiply into the three
types of blood cells; white blood cells, red blood cells and
platelets. These cells are important in fighting infection,
transporting oxygen and clotting. After the stem cells are
collected, they are processed and stored while the patient
receives high dose chemotherapy and/or radiation
therapy. This high-dose treatment disrupts the bone
marrow’s ability to make blood cells. Therefore, the stem
cells are reinfused to repopulate the bone marrow and
restore the patient’s ability to make blood cells.
These therapies are among the exciting treatments available to patients in the cancer program at St. Luke’s Medi
cal Center.
Marija Barthel, RN., B.S.N.
Vince Lombardi Cancer Clinic

A Blood Cell Separator aids in the treatment of
a variety of cancers.
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The Immunotherapy Program

The Immunotherapy Program at St. Luke’s continues to
provide innovative cancer care as one of the few commu
nity hospitals in the country offering this exciting treatment modality.
Offering both Phase I and Phase II clinical trials, we have
treated a growing number of patients using Alpha Interferon and Interleukin-2 along with activated white blood
cells (TIL or LAK cells) to destroy cancer throughout the
body. These treatments are now considered standard
therapy for metastatic melanoma and renal cell carcinoma,
but can be effective against a number of other malignan
cies as well (refractory lymphoma, cancers of the bladder,
lung, colon, liver and biliary tract). In addition to these
studies, we have recently become a participant in a nationwide Phase III clinical trial comparing a melanoma vac
cine to combination chemotherapy in patients with widespread disease.
Great strides were made in heightening both public and
professional awareness of immunotherapy in the commu
nity and beyond. Through lectures, media support and
networking, we have established a broadened referral base
while educating both physicians and patients about this
exciting area of cancer therapy. Currently, over 60% of
our immunotherapy patients treated here are from outside
of Wisconsin.
Full operation of our new Immunology Research Labora
tory began in 1991. Basic science research taking place at
the lab will help provide scientific discoveries which will
aid advances in patient treatment. The future direction of
this facility will seek innovative methods to enhance the
body’s own immune system utilizing the latest technolo
gies from molecular biology and cellular immunology.
The ongoing work at this level will provide support essen
tial to the development of new immunotherapy trials.
Immunotherapy as the fourth treatment modality, will
continue to evolve as a leader among new cancer thera
pies. Through continued recognition by the medical
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community, results from immunotherapy clinical trials
will lead to a broadened use of this option as a recognized
standard therapy.
This was most recently evidenced by the recommendation
of the FDA’s Biological Response Modifiers Advisory
Committee to provide Interleukin-2 as an effective treatment of widespread renal cell carcinoma. This is a great
accomplishment in which St. Luke’s is proud to have been
a part.
Carol Rausch, RN.
Immunotherapy Program
Carla Rohioff, RN.
Immunotherapy Program

r
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Dr. John P. Hanson, Jr., Director ofthe Immunotherapy
Program at St. Luke’s Medical Center, examines a patient.
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Ovarian Cancer: A Familial
Link

While we have treatment modalities
that effectively treat and/or cure
ovarian cancer in its early stage, diag
nosing it in early stages is the excep
tion, and not the rule. Further, of all
the risk factors for ovarian cancer, the
greatest risk factor, is that of familial
tendency, a first-degree relative with
ovarian cancer.
Angela a Kliinaszewski,
M.S.N., RN., O.CN.

Gene Wilder was afeatured speaker at a St. Luke’s
Medical Center sponsored conference “Ovarian
Cancer: A Familial Link.”

KerryA. Twite,
M.S.N., R.N., O.C.N.

Gene Wilder, actor, director, writer and
Honorary Chairman of the Gilda
Radner Familial Ovarian Cancer
Registry, Dr. M. Steven Piver, Director
of the Registry and Dr. Ronald Hart,
Director of St. Luke’s Medical Center’s
Vince Lombardi Cancer Clinic were
brought together on Wednesday, April
10th, at the Pfister Hotel to discuss,
“Ovarian Cancer: A Familial Link”.
The presentation was the opening
ceremony of a two-day nursing conference on “Cancer: A Woman’s Issue”
and was open to the public as part of
the Vince Lombardi Cancer Clinic
Community Lecture Series. Over 500
people attended the panel presentation.

Mr. Wilder shared his and Gilda’s experience with ovarian
cancer. He eloquently shared his discovery of the Familial
Ovarian Cancer Registry at Roswell Park Cancer Institute
in Buffalo, New York, after Gilda’s death, of how it was re
named in her honor, and how he met, befriended and
took-on the fight against ovarian cancer with his “sidekick” Dr. M. Steven Piver.
Dr. Piver began by noting that there had only been five
reports of familial ovarian cancer (two or more close
relatives) reported in the literature between 1929 and 1979
when he started the Registry in 1981. After Mr. Wilder’s
first public service announcement aired in 1990, containing
the Registry’s 1-800-OVARIAN number, over 27,000 calls
were recieved in the next 30 days. As of May 31, 1990, a
total of 435 families and 1020 cases of familial ovarian
cancer have been registered.
The Registry reports that women with two or more firstdegree relatives (mother, sister, daughter) with ovarian
cancer may have as high as a 50% chance of developing the
disease, compared to the 1.4% chance for women without a
family history. The Registry recommends prophylactic
oophorectomy by age 35 for these women, if they have
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completed their family. Ovarian cancer in second-degree
relatives (grandmother, aunts) and more distant relatives
are recorded in the Registry. Surveillance at a young age
and prophylactic oophorectomy after age 35 are recom
mended for women with one first-degree and one seconddegree or two or more second-degree relatives with ovar
ian cancer.
Women at high risk (first-degree relatives) should receive
genetic counseling in their early twenties. Pelvic and
abdominal exams, CA 125 and pelvic ultrasound should be
done every six months once they reach the age of thirty.
The same holds true for women whose mother or grandmother or two or more aunts or an aunt and a daughter
had ovarian cancer.
Dr. Ronald Hart presented data from Milwaukee on ovar
ian cancer. Age at diagnosis ranges from 19 to 80, with the
40-79 year old age group being the most commonly af
fected. Dr. Hart noted that while ovarian cancer represents
only 4% of all cancers among women, it will cause more
deaths than any other cancer of the female reproductive
system. In Wisconsin, there are 371 new cases and 247
deaths annually. Dr. Hart stressed that: a) this is not a
disease of the elderly, b) it is a common disease with a
large impact, c) family history is important, d) absence of
family history is not reassuring, e) early stage patients
usually do have symptoms, f) routine pelvic exams are
warranted for all individuals, especially those at risk and,
g) multidisciplinary treatment planning is a must.
Women who attended the panel presentation found that
many women in the audience shared similar experiences in
their struggle to obtain early diagnosis. This shared
experience served as a bond for several who challenged
St. Luke’s Medical Center to provide a support group for
those who were at risk for ovarian cancer as well as those
who struggle to beat cancer. In June 1991, the first meeting
of the ovarian cancer awareness group was held. Women
told their stories of diagnosis and treatment, and shared
their feelings. The meeting ended with a moving letter
read to the group by a nurse who had been treated for
ovarian cancer over 10 years ago. The Ovarian Cancer
Support Group meets on the first Tuesday of each month,
in the Vince Lombardi Cancer Clinic.
Angela D. Klimaszewski, M.S.N., RN., O.C.N.
Cancer Research Coordinator
Kerry A. Twite, M.S.N., RN., O.C.N.
Clinical Nurse Specialist, Oncology
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School of Radiation Therapy
T chnol 3

the manpower shortage (of Radia
tion Therapists) in Radiation Therapy
is an important national healthcare
issue which must be addressed
American College of Radiology
January 1990
“
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The Oncology Program at St. Luke’s
Medical Center has been targeted as a
growing, progressive leader of cancer
care in the community. They offer a
variety of state of the art cancer treatments including radiation therapy.
Radiation therapy requires skilled and certified Radiation
Therapists to administer radiation treatments to cancer
patients; so, the staff shortage is a concern of St. Luke’s
Medical Center.

Students at St. Luke’s Medical Center’s School of
Radiation Therapy Technology engage in extensive
clinical experiences during their training.

Efforts to develop a training program for Radiation Thera
pists were spearheaded by Dr. Marcia Richards, Medical
Director of Radiation Oncology and supported by the
administration of St. Luke’s Medical Center. In September,
1990, the school of Radiation Therapy Technology opened
its doors in hopes of addressing the critical staff shortage
of these therapists in the cancer care community.
The school is a twelve-month certification program which
trains highly skilled therapists to administer radiation
treatments to cancer patients. The intensive training
involves studies in math, physics, radiobiology, pathology,
oncology, ethics, anatomy and physiology, radiation
protection, and nursing. Students engage in extensive
clinical experiences which develop their technical skills
and the compassion and caring attitude required in this
challenging, specialized field.
The program accepts four to eight students per year from
candidates around the state and the country who meet
stringent admission criteria.
The expertise of the Radiation Oncology staff, the variety
of clinical experiences, and the progressive atmosphere of
the Radiation Oncology department at St. Luke’s Medical
Center will prepare Radiation Therapists for the challenges
that lie ahead of them in helping patients with their battle
against cancer.
Pam Kresl, R.T.T.
Radiation Oncology
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High-dose combination chemotherapy
with autologous bone marrow
reinfusion (HDC/ABMR) and periph
eral stem cell support has been available at St. Luke’s Medical Center as a
treatment option since early 1991 for
women with advanced or recurrent
breast cancer. Eleven patients have
been treated on two active protocols to
date. These women were either at high
risk for recurrence (greater than 10
Kathy Qidharn, RN.,
positive lymph nodes or other poor
B.S.N., O.C.N.
prognostic factors) or had recurrent!
metastatic disease. Recurrent breast
cancer is incurable using standard therapy. HDC/ABMR
offers these women a chance for long-term, disease-free
survival. This treatment modality can also be used as
adjuvant therapy in women who are at high risk for recurrence, hopefully preventing recurrence and metastasis.
The two protocols available at St. Luke’s Medical Center
for the treatment of breast cancer with HDC/ABMR
involved (1) the surgical collection of bone marrow stem
cells, (2) the collection of peripheral stem cells through
pheresis, (3) freezing and storage of these cells, (4) admin
istration of high-dose combination chemotherapy and (5)
subsequent reinfusion of both bone marrow and peripher
ally derived stem cells. Hematopoietic growth factors are
administered to increase the number of stem cells available for collection during pheresis and to decrease the
period of neutropenia following bone marrow reinfusion.
Patients treated with growth factors appear to recover
their white blood cell counts more quickly than those
patients who do not receive growth factors. The use of
growth factors appears to have decreased the hospital
length of stay, in general, for patients being treated with
HDC /ABMR.
The patients treated with HDC/ABMR for breast cancer
are overall doing well. We hope that through continued
improvements in supportive care, development of new
technologies and more effective combination chemo
therapy/radiation regimens, results will continue to
improve.
Kathy Oldham, RN., B.S.N., O.C.N.
ABMR Coordinator
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Treatment For Advanced or
Recurrent Breast Cancer
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Dr. Ajit Divgi and Dr. Robert Taylor surgically
collect bone marrow stem cells.

New Development

Vince Lombardi Cancer
Clinic Program Review

The Vince Lombardi Cancer Clinic was
dedicated at St. Luk&s Medical Center in
care and treatment, the Vince Lombardi
Memorial Classic funds enable us to focus
on cancer prevention, detection, education
and research.

:

The Vince Lombardi Cancer Clinic is the
entry point for nearly 950 new cancer
a year who receive about 12,000
patients
Nancy Nowak RN., MA.
treatments. These services include chemo
therapy treatments, immunotherapy,
counseling and support services.
::

.

Each year the Vince Lombardi Lecture Series offers community
education programs on such topics as cancer prevention, nutri
tion and site specific programs such as prostate and breast
cancer. In order to keep physicians and health professionals
aware of the latest cancer treatments, the clinic publishes a
newsletter three times a year which is circulated to approxi
mately 5,000 health professionals in the state of Wisconsin.
Individual cancer education and information is available through
the Cancer Hotline. Phone calls to the hotline come from the
general public, cancer patients and their families, and health
professionals.
Because we know that early detection can affect an individual’s
survival from cancer, the clinic participates in a number of
community health fairs, and offers public screening programs for
such cancers as prostate, skin, colorectal and head and neck.
Research is another commitment of the Vince Lombardi Clinic.
Each year physicians and nurses participate in a variety of
research studies which look at cancer prevention and detection as
well as cancer treatment and symptom management.
We believe that the key to saving the “Vince Lombardi’s’ of the
future from untimely cancer deaths lies in establishing services
that will make cancer a preventable and controllable disease. The
Vince Lombardi Cancer Clinic at St. Luke’s Medical Center is
actively striving to make that vision a reality.
Nancy Nowak, RN., MA.
Cancer Program Manager
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New Developments

Vince Lombardi Cancer Clinic Sponsored
Activities:

Active patient care and treatment

A health fairfor community education.

An informative newsietterfor health professionals

Individual education and information through the
Cancer Hotline.
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Glossary
Analytic Cases; Cases which are first diagnosed
and/or given their first course of treatment at St.
Luke’s Medical Center.

Hormone Therapy; In prostate cancer, treatment
that reduces the male hormone which promotes
prostate tumor growth.

Androgen Hormone; Any hormone that produces
male physical characteristics (facial hair, deep voice,
etc.). The main androgen hormone is testosterone.

Impotence; Inability to have an erection.
Incontinence; A loss of urinary control.

Antiandrogen Drug; A drug that blocks the activ
ity of an androgen hormone.

In situ; A tumor classified microscopically as in
situ, non-invasive, pre-invasive, non-infiltrating,
intraductal, intraepithelial or intraepidermal.

Benign; A term for a tumor that does not normally
threaten a person’s life (that is, a tumor that is not
cancerous and does not attack).

Interstitial Radiation Therapy; Treatment with
high-energy radiation from tiny radioactive seeds
inserted into the tumor.

Bladder; The hollow organ that stores urine.

Local Stage; Tumor restricted to the organ of
origin, but may be invasive or infiltrating within
the organ of origin.

Cancer; A tumor that attacks and poses a serious
threat to a person’s life.
Capsule; The layer of cells around an organ such as
the prostate.

Luteinizing Hormone; A hormone secreted by
the pituitary gland that stimulates the secretion of
sex hormones in both men and women. Also
called LH.

Cells; The basic structural and functional units of
the body.

LHRH Analogue; Man-made compounds that
are similar to natural LHRH.

Chemotherapy; Treatment with powerful drugs
that attack cancer cells.

Lymph; A nearly clear fluid collected from tissues
around the body and returned to the blood via the
lymphatic system.

Combined Therapy; Refers to any combination of
surgery, radiation, chemotherapy, hormone therapy
or other therapy administered jointly as a single
course of treatment.
Diagnostic Only; Cancer related treatment was not
given; this may occur for many reason; for example,
the patient refused treatment, or the patient’s general
condition is unsatisfactory for treatment.
Distant Stage; A neoplasm that has spread to other
organs or lymph nodes remote from the primary
tumor.

Lymphatic System; vessels that carry lymph,
together with lymph nodes and several organs that
produce and store infection-fighting cells.
Lymph Nodes; Small bean-shaped structures
scattered along the vessels of the lymphatic sys
tem. The nodes filter bacteria and cancer cells that
may travel through the system.
Malignant; A term for a tumor that can threaten a
person’s life; that is a tumor that is cancerous.
Malignant has the same meaning as cancerous.
,

Estrogen; A female sex hormone.
External Radiation Therapy; Radiation therapy
that uses rays from a machine.

Metastasis; The spread of cancer from its original
site to distant areas. The cancer cells are carried to
distant sites by blood and lymph.

First Course of Treatment; The tumor directed
treatments started within the first four months after
diagnosis.

Glossary continued on next page
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Glossary

Non-Analytical; Cases which are seen at St.
Luke’s Medical Center after the first course of
treatment.

Transurethral Resection; The use of a special
instrument inserted through the urethra in the penis
to remove a small prostate tumor. Also called TUR

Oncologist; A doctor who specializes in treating
cancer.

Tumor; An excessive growth of cells resulting from
uncontrolled and disorderly cell replacement.

Orchiectomy; The surgical removal of the testicles.

Ureter; The tube that carries urine from each kidney
to the bladder.

Prostatectomy; The surgical removal of the prostate gland.
Radiation Therapy; Treatment with high-energy
radiation from x-rays or other sources of radiation.
Regional Stage; A tumor that has extended
beyond the limits of the organ of origin into 1)
surrounding organs or tissues by direct extension,
2) regional lymph nodes by metastasis, 3) or a
combination of 1) and 2) and appears to have
spread no further.

Urethra; The tube that carries urine from the blad
der and semen from the sex glands to the outside of
the body.
Urologist; A doctor who specializes in urologic
cancer, such as prostate cancer, and in diseases of
the urinary organs in women and both the urinary
and sex organs in men.

Scrotum; The external bag or pouch containing the
testicles.

Seminal Vesicles; The pouches above the prostate
that store semen.
Stage; A term used to describe the size and extent
of spread of the cancer.
Staging; Tests conducted to determine the stage of
a cancer.
Surgery; The partial or total removal of the tumor
excluding a biopsy.
Testicles; Two egg-shaped glands that produce
sperm and sex hormones.
Testosterone; A male sex hormone produced
chiefly by the testicles. Testosterone stimulates a
man’s sexual activity and the growth of other sex
organs, including the prostate.
Tissue; A group of cells organized to perform a
specialized function.
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Annual Program Supplement-Cancer Program Statistics-1990
Cancer Registry Report
In 1990, 1,371 new patients were accessioned into the
St. Luke’s Medical Center Cancer Registry: 1,210 analytic,
161 non-analytic. This brings the registry to a total of
over 17,000 patients. The registry has worked closely
with the physicians to maintain a 9$% follow-up rate
and the growing data base now offers more data oppor
tunities to varied requestors than ever before. We have
accessed the data to participate in the Quality Assurance
Survey for Localized Prostate Cancer and Long/Short
Term Patient Care Evaluations for Ovarian Cancer. The
updated CanSur 3.0 software version installed in 1989
has improved access to statistical reports and assisted in
presenting the graphs and charts on the following pages.
These graphs and charts present a brief overview of
cancer diagnosis and treatment at St. Luke’s Medical
Center.
Any questions or requests for information may be
directed to 649-6720.
Sandy Blixt, R.RA.
Cancer Registrar

1990 Site Distribution
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This site distribution presents
Breast Cancer as the most
frequently diagnosed cancer site in
1990. A comparison ;;iade to the
same distribution in 1989 revealed
Lung Cancer as the most frequent
site and Breast Cancer as a very
close second.
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Cancer Registry Report
New Case Distribution By Age

AGE AT DIAGNOSJS
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Total number of patients accessioned: 1,371
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The age distribution presents the age group of
55 to 84 as the largest percentage of
accessioned population at St. Luke’s Medical
Center. The patientsfrom ages 55 to $4 make
up 73% ofthe new casesfor 1990.
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1990 General Summary Stage for All Sites

LOCAL 43.3%

DISTANT 20.2%

Insitu
Localized
Regional
Distant
Unknown
TOTAL

UF\IF<NOWN 3.7%

CASES
71
593
379
277
51

5.2%
43.3%
27.6%
20.2%
3.7%

1371

NSI7U 5.2%
REGIONAL 27.6%

The graph represents the General Summary
Stage at diagnosisfor patients entered into the
registry in 1990. Over 40% ofthose patients
diagnosed had a Local Stage malignancy.
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St. Luke’s Medical Center Cancer Research
ABMR PROTOCOLS
High Dose VP-16, Cytoxan, TBI and Autologous Bone
Marrow Transplant for Resistant Non-Hodgkin ‘
Lymphoma
R. Taylor, M.D., 2/90, ongoing

CALGB #9194 Phase III Comparison of Adjuvant
Chemoendocrine Therapy with CAF and Concurrent or
Delayed Tamoxifen to Tamoxifen Alone in Postmeno
pausal Patients with Involved Axillary Lymph Nodes
and Positive Receptors
R. Hart, M.D., 5/10/91

High Dose Chemotherapy with Autologous Bone Marrow
CALGB #9193 Phase III Comparison of Cyclophospha
Reinfusion for Patients with Refractory Hodgkin’s
mide, Doxorubicin, and 5-FU (CAF) and a 16 week
Disease
Regimen as Adjuvant Therapy for Patients
Multi-Drug
R Taylor, M.D., 2/90, ongoing
With Hormone Receptor Negative
Autologous Bone Marrow Transplant for Early Recurrent R. Hart, M.D., 7/12/91
Breast Carcinoma
CALGB #9041 Subcutaneously Administered Recombi
R. Taylor, M.D., 3/91, ongoing
nant Human Interleukin 2 and Interferon Alfa-2A for
High Dose Intensification and Autologous Hematopoietic Advanced Breast Cancer-A Phase II Study
R. Hart, M.D., 9/6/91
Stem Cell Reinfusion in Advanced Breast Cancer
R. Taylor, M.D., 6/91, ongoing
CALGB #9192 Phase III Comparison of Combination
Therapy
A Randomized, Double-Blinded, Placebo-Controlled Trial Chemotherapy (CAF) and Chemohormonal
+ Zoladex + Tamoxifen) in
CAF
or
+
Zoladex
(CAF
Following
GM-CSF
Human
of
with Two Dosage Levels
Positive
Autologous Bone Marrow Reconstitution for Lymphoma Premenopausal Women With Axillary Node
Cancer
Breast
Positive
Receptor
R. Taylor, M.D., 11/90 to 11/91
R. Hart, M.D., 12/13/91
High Dose BCNU andABMT for Malignant Glioma
COLORECTAL
R. Taylor, M.D., late 1991, ongoing
CALGB #8966 Laboratory Studies on Frozen Tumor
Tissue of Colorectal Carcinoma
CALGB PROTOCOLS
R. Hart, M.D., 4/13/90
E
MYELODYSPLASTIC SYNDROM
CALGB #8965 Utility of Flow Cytometric DNA Content
CALGB #9092 Phase III protocol for the Evaluation of 5and Reticulocyte Analysis as Prognostic Indicators in
FU vs. 5-FU + PALA or 5-FU + Oral Leucovorin or 5-FU
Myelodysplastic Syndromes
+ Intravenous Leucovorin or 5-FU + rIFNa-2a in Patients
R. Hart, M.D., 1/12/90
with Advanced Colorectal Cancer
R. Hart, M.D., 7/12/91
BREAST
CALGB #8622 (Re-activated) Monitoring Circulating
LYMPHOMA
Breast Cancer Associated Antigens with the 15-3
CALGB #9061 Clinical Significance of Bcl-2 RearrangeCancer
Breast
in
Metastatic
oassy
Radioimmun
ments in Lymphoma Utilizing the Polymerase Chain
R. Hart, M.D., 1/29/90
Reaction
R. Hart, M.D., 6/8/90
CALGB #9082 A Randomized Comparative Study of
Adjuvant CAF Followed by Standard CPA/cDDP/BCNU
vs. Intensive CAPA/cDDP/BCNU Plus Autologous Bone LEUKEMIA
Marrow Support with Local Regional Radiation Therapy CALGB #9021 High Dose Cytarabine with or without
Concurrent GM-CSF in the Remission of Induction of
and Hormonal Therapy for Patients with Stage 11/111
Relapsed or Refractory Acute Myelogenous Leukemia
Nodes
Lymph
10
more
or
Breast Cancer Involving
and Untreated Blast Crisis of Chronic Myelogenous
R. Hart, M.D., 1/11/91
Leukemia A Phase III Study
CALGB #8944 Intensive Doxorubicin, Surgery, CMF, and R. Hart, M.D., 12/14/90
Radiation Therapy for Stage III Breast Cancer A Study of
Efficacy with Pharmacokinetic and Antigenic Monitoring LUNG
CALGB #9033 Oral vs. Intravenous Etoposide in Combi
Phase II
with Intravenous Cisplatin in Extensive Small
nation
R. Hart, M.D., 11/9/90
Cell Lung Cancer: Phase III, Includes Pharmacology
Companion Protocol CALGB #9062
R. Hart, M.D., 1/11/91
-

-

-

-
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CALGB #9132 Ifosfamide/MESNA/Cisplatin or
Etoposide/ Cisplatin + G-CSF in Advanced Non-Small
Cell Lung Cancer (NSCLC): A Phase II Study ‘
R. Hart, M.D., 9/6/91
OTHER
CALGB #9072 Smoking Cessation in Relatives of Cancer
Patients A Pilot Study of Intervention by Patients and
Oncologists
R. Hart, M.D., 6/14/91
-

IMMUNOTHERAPY PROTOCOLS
MELANOMA
A Randomized Phase III Trial of Melacine vs. Chemo
therapy in Patients With Disseminated Malignant
Melanoma (BRM-91-0002)
J.P. Hanson, M.D.
MELANOMA AND RENAL
Tumor Infiltrating Lymphocyte Therapy for Advanced
Melanoma and Renal Cancer (BRM 89-0001)
J.P. Hanson, M.D., 9/8/89
UROEPITHELIAL
IL-2/LAK Cell Therapy for Advanced Uroepithehal
Cancers (BRM-90-01)
J.P. Hanson, M.D., 3/9/90
OTHER
Alpha Interferon Pretreatment in IL-2/LAK Therapy for
Advanced Cancer (BRM-89-0002)
J.P.Hanson, M.D., 1/12/90
PDQ LISTINGS
MELANOMA OR RENAL
STLMC-BRM-89-0001, NCI-V90-0025
Phase II Study of Tumor Infiltrating Lymphocytes in
Patients With Advanced Melanoma or Renal Cancer
J.P. Hanson, M.D.
RADIATION ONCOLOGY PROTOCOLS
BRAIN
FLUOSOL -P0 9132-A: A Controlled Phase II Study:
Fluosol as an Adjuvant to Stereotactic Radiosurgery in
the Treatment of Solitary Brain Metastasis
M. Pincus, M.D., 8/9/91
OTHER
Clinical Study -SAL 89-01, Salitron System, Multi-center
Clinical Study Program of Efficacy and Safety in Patients
with Xerostomia due to various Etiologies other than
Sjogren’s Syndrome
J. Bruckman, M.D., 2/9/90

OTHER PROTOCOLS
LEUKEMIA
Group C Protocol: Fludarabine Phosphate in Patients
with Refractory Chronic Lymphocytic Leukemia
J.P. Hanson, M.D., 4/13/90
BREAST
NSABP B24: A Clinical Trial to Evaluate the Worth of
Tamoxifen in Conjunction with Lumpectomy and Breast
Irradiation for the Treatment of Non-Invasive Intraductal
Carcinoma (DCIS) of the Breast
R. Hart, M.D., 7/12/91
URCC 1190M: Control of Vasomotor Symptoms Associ
ated with Tamoxifen Therapy in Women with Breast
Cancer
R. Hart, M.D., 12/13/91
LUNG
A Double-Blind, Randomized, Placebo Controlled,
Multicenter Study of Diethyldithiocarbanate (DDTC)
Used as a Protective Agent Against Cisplatin-Induced
Toxicities in Patients with Small Cell and Non Small Cell
Lung Cancer
R. Hart, M.D., 10/11/91
OVARY
A Double-Blind, Randomized, Placebo Controlled,
Multicenter Study of Diethyldithiocarbanate (DDTC)
Used as a Protective Agent Against Cisplatin-Induced
Toxicities in Patients With Ovarian Cancer
R. Hart, M.D., 10/11/91
OTHER
URCC 2790: Fluoxetine (Prozac) as a Co-analgesic
R. Hart, M.D., 12/13/91
CUI-019003: A Randomized, Double-Blind, Parallel
Group Study of MAROGEN Sterile Powder (100 lU/kg
& 200 lU/kg) vs. Placebo in the Treatment of Anemia
Associated with Chemotherapy
R. Hart, M.D., 1/11/91
Trial to Reduce Alloimmunization to Platelets (TRAP)
Sponsor: Dr. Taylor for the Blood Center of SE Wisconsin
R. Taylor, M.D., 2/8/91
A. Divgi, M.D., has referred 30% of the projected 1991
goal of the Blood Center of Southeast Wisconsin.

I
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Vince Lombardi Cancer Clinic Cancer Research
CANCER CONTROL RESEARCH
Active Protocols
Community Compliance with Cancer Screening Recommendations
Smoking Cessation Training for House Officers
Impact of Nursing Intervention in Breast Self Examination
Assessment of Hope in the Adult Cancer Patient
A Test of the Smoke Free Madres Smoking Cessation Program
Sandostatin, 5FU,LV for Advanced Colon Cancer

Hart
Laufenberg
Muchka
Utecht
Pletsch
Hart

Pending Activation
Radiation Dermatitis
Effect of Interpersonal Counselling on Quality of Life
Dietary Counselling in Adjuvant Breast Cancer
Topical Anesthesia Prior to Venipuncture

Pinkus
Muchka
Thompson
Hart

NATIONAL RESEARCH TRIALS
Leukemia
AML, New Standard Induction HiDAC, CYT/VP-16, DHAD/AZQ
AML, AGE 60, GM-CSF vs Placebo during Standard Induction
ALL, New Five Drug Induction = Consolidation
Mult Myel, CBDCA
CLL, Fludarabine vs Chlorambucil vs Fludarabine + Chlorambucil
CML, Ara C, Alfa Interferon

CALGB
CALGB
CALGB
CALGB
CALBG
CALGB

Lymphoma
Hodgkins, New Dx, I-TI, Etoposide, Vinblastine, Adriamycin +RT
Hodgkins, New Dx, 111-TV, ABVD vs MOPP/ABV Hybrid
NHL, New Dx NPDL, Cytoxan vs Cytoxan + Interferon
NHL, Relapsed, Hydroxyurea + AraC

CALGB 9051
Inter Group $952
CALGB $691
CALGB 8951

Lung
Small Cell Limited, ACE x 3 then PCE+RT +1- Warfarin
Small Cell Limited, Hyperfractionation RT + CT
Small Cell Extensive, PACE + 1L2
Small Cell Resected, Solitary Pulm Nodule Natural History
Non Small Cell Regional, CT->SURGERY->RT
Non Small Cell Advance, CisPlatin + Vinblastine + Oral Hydrazine
Mesothelioma, Trimetrexate

CALGB
CALGB
CALGB
CALGB
CALGB
CALGB
CALGB

-

6

9022
$923
$811
$911
9011
9013

8534
$837
$835
$867
$935
8931
8933
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NATIONAL RESEARCH TRIALS
Colon
Stage C 1,C2, Obst’s B2, Fu Lv Vs Fu High Lv Vs Fu Lev Vs Fu Lv Lev
Rectal B2 + C, Post Op 5FU LV and Radiation

Inter Group $896
Inter Group 9081

Other Sites
Bladder, Cystectomy vs Neoadjuvant M-VAC + Cystectomy
Testicular, Cisplatin and VP-16 with Bleo or Ifosphamide

CALGB $891
Inter-Group 8991

Cancer Control
Cancer Cachexia Megace, Three dose level Trial In Lung, Colon Ca
Severe Pain, Continuous Infusion MS vs PCA MS
Prostate, Limited Disease, Coping with Prostate Radiation
First Line Chemotherapy, Managing Chemotherapy Side Effects
First Line Chemotherapy, Anxiety In Chemotherapy Side Effects
Loc-Regional Breast Cancer, Can Alkaline Phos Predict Relapse

CALGB 8971
CALGB $872
URCC C-Of
URCC C-02
URCC 2988P
URCC 21 82M

Presentations at National Conferences
Nursing
ONS Congress, Washington, D.C., May, 1990
“Photodynamic Therapy A Nursing Protocol”
Lynn Marzinski, RN. St. Luke’s Medical Center, 8GHJK
-

-

“A Method of Charging Patients in an Ambulatory Oncology Setting”
Marija Barthel, RN., B.S.N. St. Luke’s Medical Center, Vince Lombardi Cancer Clinic
-

“Charting by Exception A Method of Documentation in an Ambulatory Oncology Setting”
Marija Barthel, RN., B.S.N. St. Luke’s Medical Center, Vince Lombardi Cancer Clinic
-

-

J
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St. Luke’s Cancer Conferences
Tumor Board Conference
Conferences are held on the second and fourth Monday of every month at noon. This is a patient oriented, multidisciplinary cancer conference. For more information or questions, please call 649-6720.

Head and Neck Tumor Conference
This is a conference to discuss selected difficult head and neck tumors from a multi-disciplinary approach. Conferences are held on the first and third Monday of every month at noon. For more information or questions, please call
649-3900

Security Savings & Loan Cancer Lectureship Series 1990
January 4, 1990

BONE MARROW TRANSPLANTATION
James 0. Armitage, M.D.
Professor & Vice Chairman
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, NE

May 24, 1990

CURRENT STATUS OF LOCAL & INTERSTITIAL HYPERTHERMIA
Carlos A. Perez, M.D.
Director, Radiation Oncology Center
Mallinckrodt Institute of Radiology
St. Louis, MO

June 21, 1990

COMBINED MODALITIES: RADIATION THERAPY & CHEMOTHERAPY
Theodore Phillips, M.D.
Professor & Chairman
Department of Radiation Oncology
Long Hospital
San Francisco, CA

September 27, 1990

THE MULTISUBUNIT IL-2 RECEPTOR: A TARGET FOR IMMUNOTHERAPY
OF LYMPHOMA, AUTOIMMUNITY AND ORGAN ALLOGRAFTS
Thomas A Waldmann, M.D.
Chief, Metabolism Branch/NCI
National Institutes of Health
Bethesda, MD
.

November 15, 1990

PITUITARY TUMORS: DIAGNOSIS AND MANAGEMENT
A. Blake Tyrrell, M.D.
Metabolic/Research Unit
University of California
San Francisco, Ca

December 6, 1990

CHEMOTHERAPY FOR CANCER: OVERCOMING THE PROBLEM OF
RESISTANCE
Vincent T. DeVita, Jr., M.D.
Physician and Chief
Benno C. Schmidt Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
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1.

Did you find this information useful?__________

2.

Ws the inforrntiori easily readable?____________________________________

3.

Did you shire this with family or friends?

4.

Suggestions:

(Optional) Nme:_
Deprtrnent:

PLEASE RETURN TO:

Incy A. Nowk
Cncet Program Maner
St. Luk&s Medical Center
2900 West Okiahomo Avenue
Milwiukee, WI 53215
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